Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography
- PMID: 14621983
- DOI: 10.1021/bi035716w
Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography
Erratum in
- Biochemistry. 2003 Dec 30;42(51):15398
Abstract
The reactions between three clinically relevant inhibitors, tazobactam, sulbactam, and clavulanic acid, and SHV beta-lactamase (EC 3.5.2.6) have been followed in single crystals using a Raman microscope. The data are far superior to those obtained for the enzyme in aqueous solution and allow us to identify species on the reaction pathway and to measure the rates of the accumulation and decay of these species. A key intermediate on the reaction pathway is an acyl enzyme formed between Ser70 and the lactam ring's C=O group. By using the E166A deacylation deficient variant of the enzyme, we were able to focus on the process of acyl enzyme formation. The Raman data show that all three inhibitors form an enamine-type acyl enzyme reaching maximal populations at 10, 22, and 29 min for sulbactam, clavulanic acid, and tazobactam, respectively. The enamine intermediate exhibits a characteristic and relatively intense band near 1595 cm(-1) due to a stretching motion of the O=C-C=C-NH moiety that shifts to lower frequency upon NH <--> ND exchange. This feature was used to follow the kinetics of enamine buildup and decay in the crystal. Quantum mechanical calculations support the assignment of the 1595 cm(-1) band, as well as several other bands, to a trans-enamine species. The Raman data also demonstrate that the lactam ring opens prior to enamine formation since the lactam ring carbonyl (C=O) peak disappears prior to the appearance of the enamine 1595 cm(-1) band. Tazobactam appears to form approximately twice as much enamine intermediate as sulbactam and clavulanic acid, which correlates with its superior performance in the clinic, a finding that may bear on future drug design.
Similar articles
-
Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.J Am Chem Soc. 2009 Feb 18;131(6):2338-47. doi: 10.1021/ja808311s. J Am Chem Soc. 2009. PMID: 19161282 Free PMC article.
-
Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.Biochemistry. 2004 Feb 3;43(4):843-8. doi: 10.1021/bi035985m. Biochemistry. 2004. PMID: 14744126
-
Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.Biochemistry. 2008 Apr 1;47(13):4094-101. doi: 10.1021/bi702348w. Epub 2008 Mar 7. Biochemistry. 2008. PMID: 18324783
-
Pharmacokinetic properties of beta-lactamase inhibitors.Int J Clin Pharmacol Ther. 1999 Feb;37(2):63-75. Int J Clin Pharmacol Ther. 1999. PMID: 10082170 Review.
-
Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum beta-lactamases.Can J Microbiol. 2004 Mar;50(3):137-65. doi: 10.1139/w03-111. Can J Microbiol. 2004. PMID: 15105882 Review.
Cited by
-
Raman spectra of interchanging β-lactamase inhibitor intermediates on the millisecond time scale.J Am Chem Soc. 2013 Feb 27;135(8):2895-8. doi: 10.1021/ja311440p. Epub 2013 Feb 18. J Am Chem Soc. 2013. PMID: 23406484 Free PMC article.
-
Role of Asp104 in the SHV beta-lactamase.Antimicrob Agents Chemother. 2006 Dec;50(12):4124-31. doi: 10.1128/AAC.00848-06. Epub 2006 Sep 18. Antimicrob Agents Chemother. 2006. PMID: 16982784 Free PMC article.
-
Mutation of the active site carboxy-lysine (K70) of OXA-1 beta-lactamase results in a deacylation-deficient enzyme.Biochemistry. 2009 Jul 7;48(26):6136-45. doi: 10.1021/bi900448u. Biochemistry. 2009. PMID: 19485421 Free PMC article.
-
Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.J Am Chem Soc. 2009 Feb 18;131(6):2338-47. doi: 10.1021/ja808311s. J Am Chem Soc. 2009. PMID: 19161282 Free PMC article.
-
Heterogeneity in M. tuberculosis β-lactamase inhibition by Sulbactam.Nat Commun. 2023 Sep 7;14(1):5507. doi: 10.1038/s41467-023-41246-1. Nat Commun. 2023. PMID: 37679343 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources